Jennifer D Brooks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1232554/publications.pdf

Version: 2024-02-01

48 papers

1,608 citations

20 h-index 39 g-index

50 all docs 50 docs citations

50 times ranked

2142 citing authors

#	Article	IF	Citations
1	Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women. Journal of the National Cancer Institute, 2022, 114, 631-634.	6.3	6
2	Platelet Count and Survival after Cancer. Cancers, 2022, 14, 549.	3.7	17
3	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	1.4	8
4	Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period. JAMA Network Open, 2022, 5, e2141633.	5.9	27
5	Association of contralateral breast cancer risk with mammographic density defined at higherâ€thanâ€conventional intensity thresholds. International Journal of Cancer, 2022, 151, 1304-1309.	5.1	3
6	Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine. Current Epidemiology Reports, 2022, 9, 200-211.	2.4	2
7	Identifying Children and Youth With Autism Spectrum Disorder in Electronic Medical Records: Examining Health System Utilization and Comorbidities. Autism Research, 2021, 14, 400-410.	3.8	16
8	Measures of Adiposity and Risk of Testing Positive for SARS-CoV-2 in the UK Biobank Study. Journal of Obesity, 2021, 2021, 1-6.	2.7	9
9	Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. Journal of Personalized Medicine, 2021, 11, 95.	2.5	28
10	Assessing the validity of administrative health data for the identification of children and youth with autism spectrum disorder in Ontario. Autism Research, 2021, 14, 1037-1045.	3.8	9
11	The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort study. PLoS ONE, 2021, 16, e0250508.	2.5	30
12	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). Journal of Personalized Medicine, 2021, 11, 511.	2.5	59
13	Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. Journal of Personalized Medicine, 2021, 11, 726.	2.5	5
14	The association of sex and calendar month with changes in weight: A retrospective cohort study of a community-based weight management clinic. Obesity Research and Clinical Practice, 2021, 15, 515-517.	1.8	1
15	The impact of chronic comorbidities at the time of breast cancer diagnosis on quality of life, and emotional health following treatment in Canada. PLoS ONE, 2021, 16, e0256536.	2.5	10
16	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. Journal of Personalized Medicine, 2021, 11, 916.	2.5	8
17	Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer. JACC: CardioOncology, 2021, 3, 381-392.	4.0	31
18	Mammographic texture features associated with contralateral breast cancer in the WECARE Study. Npj Breast Cancer, 2021, 7, 146.	5.2	1

#	Article	IF	CITATIONS
19	Association between maternal acetaminophen use and adverse birth outcomes in a pregnancy and birth cohort. Pediatric Research, 2020, 87, 1263-1269.	2.3	9
20	Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Research, 2020, 22, 138.	5.0	10
21	A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study. Breast, 2020, 54, 62-69.	2.2	3
22	Association between maternal cannabis use and birth outcomes: an observational study. BMC Pregnancy and Childbirth, 2020, 20, 771.	2.4	19
23	Radiation Treatment, <i>ATM</i> , <i>BRCA1/2</i> , and <i>CHEK2</i> *1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 1275-1279.	6.3	21
24	Statistical power in COVID-19 case-control host genomic study design. Genome Medicine, 2020, 12, 115.	8.2	7
25	Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer. JAMA Network Open, 2019, 2, e1912259.	5.9	5
26	MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women. International Journal of Cancer, 2018, 143, 823-830.	5.1	23
27	CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Research, 2018, 20, 149.	5.0	11
28	The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Research, 2018, 20, 23.	5.0	24
29	Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. Breast Cancer Research and Treatment, 2018, 172, 487-496.	2.5	29
30	Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. Journal of the National Cancer Institute, 2017, 109, .	6.3	28
31	Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study. International Journal of Cancer, 2017, 141, 916-924.	5.1	31
32	Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Research, 2017, 19, 83.	5.0	27
33	Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results. Radiology, 2016, 280, 716-722.	7.3	108
34	Body mass index, weight change, and risk of second primary breast cancer in the <scp>WECARE</scp> study: influence of estrogen receptor status of the first breast cancer. Cancer Medicine, 2016, 5, 3282-3291.	2.8	22
35	Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Research, 2016, 18, 65.	5.0	33
36	Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. SpringerPlus, 2015, 4, 825.	1.2	18

#	Article	IF	CITATIONS
37	Impact of fibroglandular tissue and background parenchymal enhancement on diffusion weighted imaging of breast lesions. European Journal of Radiology, 2014, 83, 2137-2143.	2.6	14
38	Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case–control study of contralateral breast cancer risk in the WECARE Study. Cancer Causes and Control, 2013, 24, 1605-1614.	1.8	6
39	Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of <i>BRCA1</i> and <i>BRCA2</i> Mutations With a Family History of Breast Cancer: A Report From the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology, 2013, 31, 433-439.	1.6	101
40	Impact of Tamoxifen on Amount of Fibroglandular Tissue, Background Parenchymal Enhancement, and Cysts on Breast Magnetic Resonance Imaging. Breast Journal, 2012, 18, 527-534.	1.0	80
41	Variation in Genes Related to Obesity, Weight, and Weight Change and Risk of Contralateral Breast Cancer in the WECARE Study Population. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2261-2267.	2.5	11
42	Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. European Radiology, 2012, 22, 2641-2647.	4.5	105
43	Reproductive Status at First Diagnosis Influences Risk of Radiation-Induced Second Primary Contralateral Breast Cancer in the WECARE Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, 917-924.	0.8	22
44	Effect of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue at Breast MR Imaging. Radiology, 2012, 264, 670-678.	7.3	74
45	Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Human Mutation, 2012, 33, 158-164.	2.5	23
46	Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Research and Treatment, 2012, 131, 571-580.	2.5	18
47	Background Parenchymal Enhancement at Breast MR Imaging and Breast Cancer Risk. Radiology, 2011, 260, 50-60.	7.3	292
48	Mammalian lignans and genistein decrease the activities of aromatase and $17\hat{1}^2$ -hydroxysteroid dehydrogenase in MCF-7 cells. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 461-467.	2.5	164